3.4 Waitlist Dropout Risk & Surveillance in HCC

Comprehensive Summary: Waitlist Dropout Risk & Surveillance in HCC

Lecturer: Prof. Sanjaya Satapathy, MD, FAASLD

Module: 3.4 – Post-Listing Management in Hepatocellular Carcinoma (HCC)

1. Main Clinical Topics Discussed

• Waitlist dropout risk stratification in HCC transplant candidates
• Mandatory surveillance protocols while listed
• Progression criteria mandating delisting
• Role of bridging therapy in preventing biologic escape
• Dynamic nature of transplant candidacy over time

2. Key Learning Points, Guidelines & Recommendations

Definition of Waitlist Dropout

• Removal from the transplant list due to:

- Tumor progression beyond transplant criteria *(most common in HCC)*

- Clinical deterioration

- Death

• Dropout reflects tumor biology + time; time functions as a biological "stress test"

Predictors of Waitlist Dropout

Tumor-Related Factors:

• Higher baseline tumor burden
• Multifocal disease
• Incomplete or poor response to locoregional therapy (LRT)

Biology-Related Factors (often more important):

• Rising AFP trend — strongest predictor of dropout
• AFP >500 ng/mL: concerning; AFP >1,000 ng/mL: high risk unless declining with therapy
• Rapid AFP doubling time indicating aggressive tumor kinetics
• AFP rebound after initial decline — suggests residual viable tumor or new aggressive disease

AFP Trend Patterns (High-Yield)

Mandatory Surveillance Protocol

• Imaging: Contrast-enhanced CT or MRI every 3 months

- Must be multi-phase (arterial + venous phases)

- LI-RADS-based interpretation required

- Single-phase CT, ultrasound, or non-contrast MRI are not acceptable

• AFP: Checked every 3 months (not every 6 months; not "as clinically indicated")
• Purpose: Early detection of progression + revalidation of exception eligibility

Progression Criteria Mandating Delisting

• New HCC lesions on surveillance imaging
• Tumor growth exceeding T2/Milan criteria
• Macrovascular invasion (e.g., portal vein tumor thrombus) — immediate disqualifier
• Extrahepatic spread (lymph nodes, lungs, bone)

Delisting Indications

• Progression beyond acceptable tumor limits
• Development of extrahepatic disease
• Macrovascular invasion
• Uncontrolled AFP despite therapy

3. Specific Clinical Data & Study Results Cited

• AFP persistently >500 ng/mL associated with poor post-transplant outcomes
• AFP >1,000 ng/mL strongly associated with dropout and poor outcomes unless it decreases with therapy
• Dropout risk rises significantly when wait time exceeds 6 months
• Sustained tumor stability over multiple imaging cycles correlates with lower recurrence risk post-transplant
• The UNOS/OPTN MELD exception and HCC exception point system is explicitly designed to balance dropout risk with allocation equity

4. Practical Takeaways for Clinicians

• Surveillance is active reselection, not passive monitoring — every 90-day imaging cycle re-validates transplant candidacy
• Stability over time = favorable biology — multiple cycles of stability are more meaningful than a single favorable scan; *one good scan is encouraging; 6 months of stability is meaningful*
• AFP dynamics > absolute AFP value — always assess trends, not isolated numbers; behavior predicts dropout
• LRT serves a dual role: therapeutic bridge AND real-time biology test — poor response to LRT signals unfavorable biology and should prompt reassessment
• Bridging therapy is strategic in patients with:

- Low lab MELD (longer anticipated wait)

- Expected wait time >6